


CLAIMS

1. A compound of formula I:



(I),

or a pharmaceutically acceptable salt thereof, wherein:

R¹ is selected from hydrogen and C₁-C₄ alkyl;

R² is selected from O and S; and

R³ is selected from -N(R⁴)-(C₃-C₆ cycloalkyl), -C₁-C₆ alkyl, -(C₀-C₄ alkylene)-heterocyclyl, and -(C₀-C₄ alkylene)-heteroaryl, wherein any alkyl, alkylene, heterocyclyl, and heteroaryl portion of R³ is optionally and independently substituted; and

R⁴ is selected from hydrogen and C₁-C₄ alkyl.

2. The compound of claim 1, wherein:

R¹ is selected from hydrogen and methyl;

R¹ is hydrogen;

R² is O; and/or

R⁴ is hydrogen.

3. The compound of Claim 1 or Claim 2, wherein R³ is selected from -N(R⁴)-(C₃-C₆ cycloalkyl), -C₃-C₆ alkyl, -(C₀-C₁ alkylene)-heterocyclyl, and -(C₀-C₁ alkylene)-heteroaryl, wherein:

any alkyl or alkylene portion of R³ is optionally and independently substituted with one or more substituents selected from the group consisting of oxo and -N(R⁵)₂, wherein each R⁵ is independently selected from hydrogen and C₁-C₄ alkyl;

any heterocyclyl portion of R³ comprises at least one nitrogen atom in a ring, and is optionally substituted with one or more substituents selected from the group consisting of C₁-C₄ alkyl and oxo; and

any heteroaryl portion of R^3 comprises at least one nitrogen atom in a ring and is optionally substituted with one or more C_1 - C_4 alkyl.

4. The compound of Claim 3, wherein:

R^3 is selected from $-C(CH_3)_3$, $-NH$ -cyclopropyl, $-CH_2$ -pyrazin-2-yl, $-pyrazin$ -2-yl, $-CH_2$ -morpholin-4-yl, and 5-methyl-1-*H*-pyrazol-4-yl;

R^3 is $-(C_0$ - C_1 alkylene)-heterocyclyl; or

R^3 is $-(C_1$ alkylene)-heterocyclyl.

5. The compound of Claim 3, wherein R^3 is $-(C_0$ - C_1 alkylene)-heterocyclyl in which:

the heterocyclyl is selected from pyrazinyl, piperidinyl, morpholinyl, and pyrazolyl; or

the heterocyclyl is morpholinyl.

6. The compound of Claim 1 or Claim 2, wherein:

(i) any alkyl, alkylene, heterocyclyl, and heteroaryl portion of R^3 is optionally and independently substituted with one or more substituents selected from the group consisting of $-OH$, $-SH$, nitro, halogen, amino, cyano, C_1 - C_{12} alkyl, C_2 - C_{12} alkenyl or C_2 - C_{12} alkynyl group, C_1 - C_{12} alkoxy, C_1 - C_{12} haloalkyl, C_1 - C_{12} haloalkoxy and C_1 - C_{12} alkyl sulfanyl;

(ii) any alkyl, alkylene, heterocyclyl, and heteroaryl portion of R^3 is optionally and independently substituted with an amino group having the formula $-N(R^5)_2$, wherein each R^5 is independently selected from hydrogen and C_1 - C_4 alkyl;

(iii) any heteroaryl portion of R^3 is optionally and independently substituted with one or more substituents selected from the group consisting of $-OH$, $-SH$, nitro, halogen, amino, cyano, C_1 - C_{12} alkyl, C_2 - C_{12} alkenyl, C_2 - C_{12} alkynyl, C_1 - C_{12} alkoxy, C_1 - C_{12} haloalkyl, C_1 - C_{12} haloalkoxy and C_1 - C_{12} alkyl sulfanyl; and

any alkyl, alkylene or heterocyclyl portion of R^3 is optionally and independently substituted with one or more substituents selected from the group consisting of oxo, $-OH$, $-SH$, nitro, halogen, amino, cyano, C_1 - C_{12} alkyl, C_2 - C_{12} alkenyl, C_2 - C_{12} alkynyl, C_1 - C_{12} alkoxy, C_1 - C_{12} haloalkyl, C_1 - C_{12} haloalkoxy and C_1 - C_{12} alkyl sulfanyl;

(iv) R^3 is selected from $-N(R^4)-(C_3-C_6 \text{ cycloalkyl})$, $-C_3-C_6 \text{ alkyl}$, $-(C_0-C_1 \text{ alkylene})\text{-heterocyclyl}$, and $-(C_0-C_1 \text{ alkylene})\text{-heteroaryl}$, wherein:

any alkyl or alkylene portion of R^3 is optionally substituted with $-N(R^5)_2$, wherein each R^5 is independently selected from hydrogen and $C_1-C_4 \text{ alkyl}$;

any heterocyclyl, and heteroaryl portion of R^3 comprises at least one nitrogen atom in a ring; and





any heterocyclyl, and heteroaryl portion of R^3 is optionally substituted with $C_1-C_4 \text{ alkyl}$;

(v) R^3 is selected from $-C(CH_3)_3$, $-\text{CH}(NH_2)\text{-CH}(CH_3)_2$, $-\text{NH-cyclopropyl}$, $-(CH_2)_{0-1}\text{-pyrazinyl}$, piperidinyl, hydroxypiperidinyl, N-methylpiperidinyl, $-\text{CH}_2\text{-morpholin-4-yl}$, and methylpyrazolyl;

(vi) R^3 is selected from $-C(CH_3)_3$, $-\text{CH}(NH_2)\text{-CH}(CH_3)_2$, $-\text{NH-cyclopropyl}$, $-(CH_2)_{0-1}\text{-pyrazin-2-yl}$, piperidin-3-yl, $-\text{CH}_2\text{-morpholin-4-yl}$, and 5-methyl-1-*H*-pyrazol-4-yl; or

(vii) R^3 is selected from $-C(CH_3)_3$, $-\text{NH-cyclopropyl}$, $-\text{CH}_2\text{-pyrazin-2-yl}$, $-\text{pyrazin-2-yl}$, $-\text{CH}_2\text{-morpholin-4-yl}$, and 5-methyl-1-*H*-pyrazol-4-yl.

7. The compound of Claim 1 represented by any one of the structural formulas set forth below:


Cmpd No.	Compound Structure	Cmpd No.	Compound Structure
1		9	
2		10	

3		11	
4		12	
5		13	
6		14	
7		15	
8			

or a pharmaceutically acceptable salt thereof.

8. The compound of Claim 7, selected from any one of compounds 1, 2, 3, 4, 8, 11, 12 and 13, or a pharmaceutically acceptable salt thereof.

9. The compound of Claim 8, represented by the following structural formula:



or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition comprising a compound of any one of Claims 1-9, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
11. A compound according to Claim 1 or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to Claim 10, for use in treating a disorder associated with CRM1 activity.
12. The compound for use or composition for use according to Claim 11, wherein the disorder is selected from a proliferative disorder, an inflammatory disorder, an autoimmune disorder, a viral infection, an ophthalmological disorder, a neurodegenerative disorder, a disorder of abnormal tissue growth, a disorder related to food intake, allergies, and a respiratory disorder.
13. The compound for use or composition for use according to Claim 12, wherein the disorder is cancer; optionally wherein the cancer is lymphoma.
14. The compound for use or composition for use according to Claim 13, wherein the compound or pharmaceutically acceptable salt thereof or the composition is to be administered together with a second therapeutic agent useful for treating cancer.
15. The compound for use or composition for use according to Claim 11, wherein:
 - the disorder is arthritis;
 - the disorder is psoriasis;
 - the disorder is obesity;
 - the disorder is stroke;
 - the disorder is traumatic brain injury; or
 - the disorder is selected from multiple sclerosis, lupus and amyotrophic lateral sclerosis.
16. A compound according to Claim 1 or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to Claim 10 for use in promoting wound healing in a subject in need thereof.
17. The pharmaceutical composition for use according to Claim 16, wherein:

the wound is a surface wound, a surgical wound, an internal wound, a chronic wound, an ulcer, a burn, or a result of radiation exposure; or

the wound is selected from the group consisting of a burn wound, an incised wound, an open wound, a surgical or post surgical wound, a diabetic lesion, a thermal burn, a chemical burn, a radiation burn, a pressure sore, a bedsore, and a condition related to diabetes or poor circulation.